WASHINGTON — The legislative saga on drug pricing is mostly over for now, but drug pricing policy will still offer plenty of controversy in 2023.
Agencies will work to implement a massive bureaucratic structure of the Inflation Reduction Act. Drugmakers who manufacture high-cost drugs will be put on the spot in a brand-new price negotiation process. Medicare will face big decisions about how to cover new drugs, and a divided Congress will be left with the leftovers of what Democrats couldn’t accomplish.
STAT has rounded up the important dates and policies to watch this year for everyone from policy wonks to patients.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
